MAAT INDEX

CLAIM #22948 · EMR (EMR) · 2025Q4 earnings call · Nov 5, 2025 · due Sep 30, 2026

the underlying health of our Software businesses remains robust with ACV expected to grow 10% plus in 2026, but having fewer contracts up for renewal adversely affects GAAP revenues.

Michael Baughman · CFO

PENDING
graded after results covering Sep 30, 2026 are reported

How to check this claim

Look at: Annual Contract Value (ACV) growth rate for Software businesses, fiscal year 2026

It came true if: ACV growth >= 10% year-over-year

Where: management commentary / investor presentation disclosing ACV growth (earnings call or supplemental slides, FY2026 results)

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2025Q4 earnings call.